A potential novel treatment for cirrhosis‐related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease
British Journal of Clinical Pharmacology · 2024-10 · 90 (10) · 2529-2538
DOI: 10.1111/bcp.16139 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.06.2024. Verfasst von Ivan Shen und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Liver Cirrhosis, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Advanced chronic liver disease and advanced chronic liver disease‐related ascites have a high mortality. The pharmacological treatment of ascites and fluid overload has changed little over time. Empagliflozin, a sodium‐glucose cotransporter type 2 inhibitor is an untested potential novel treatment in cirrhosis, as it has survival benefits in heart failure, which has similar pathophysiological fluid overload mechanisms. Before investigating empagliflozin's potential benefit in cirrhosis, its safety must be addressed.
Methods
Ten participants (five each with compensated or decompensated advanced chronic liver disease, based on Child–Pugh class) received empagliflozin 10 mg orally daily for 4 weeks with 2 weeks follow‐up. Empagliflozin safety, pharmacokinetics and pharmacodynamics were investigated.
Results
In total, eight patients (80%) reported an adverse event, and three patients (30%) experienced a serious adverse event, one of which was attributed to empagliflozin. Overall, the frequency of adverse events was similar to previous phase 3 trials of gliflozins. Higher plasma empagliflozin concentrations did not significantly increase the risk of adverse events.
Conclusions
Four‐week treatment with empagliflozin was safe and well tolerated in patients with advanced chronic liver disease. These preliminary data support assessment of long‐term treatment on disease‐related and mortality outcomes in patients with cirrhosis through randomized control trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of New South Wales, Sydney, Australia.
- Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, Australia.
- Faculty of Medicine, University of New South Wales, Sydney, Australia.
- Stats Central, Mark Wainwright Analytical Centre, University of New South Wales, Sydney, Australia.
- Department of Gastroenterology, St Vincent's Hospital, Sydney, Australia.
- Department of Clinical Pharmacology, University Medical Centre Groningen, the Netherlands.
ORCID-Profile: Ivan Shen, Jerry R Greenfield, Richard Day
Zitieren
APA
Shen, I., Stojanova, J., Yeo, M., Olsen, N., Lockart, I., Wang, M., Roggeveld, J., Heerspink, H. J. L., Greenfield, J. R., Day, R., & Danta, M. (2024). A potential novel treatment for cirrhosis‐related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease. British Journal of Clinical Pharmacology, 90(10), 2529-2538. https://doi.org/10.1111/bcp.16139
Vancouver
Shen I, Stojanova J, Yeo M, Olsen N, Lockart I, Wang M, et al. A potential novel treatment for cirrhosis‐related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease. British Journal of Clinical Pharmacology. 2024;90(10):2529-2538. doi:10.1111/bcp.16139
BibTeX
@article{Shen2024,
author = {Shen, Ivan and Stojanova, Jana and Yeo, Malcolm and Olsen, Nick and Lockart, Ian and Wang, Max and Roggeveld, Jan and Heerspink, Hiddo J L and Greenfield, Jerry R and Day, Richard and Danta, Mark},
title = {A potential novel treatment for cirrhosis‐related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
volume = {90},
number = {10},
pages = {2529--2538},
doi = {10.1111/bcp.16139}
}
EUVIMED